Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

4238 - Prognosis of diffuse large B-cell lymphoma: 16 years of experience


08 Oct 2016


Poster Display


Ece Esin


Annals of Oncology (2016) 27 (6): 313-327. 10.1093/annonc/mdw375


E. Esin1, A. Saglam2, M. Hayran3, A. Uner2

Author affiliations

  • 1 Medical Oncology Dep., Hacettepe University Faculty of Medicine, 06100 - Ankara/TR
  • 2 Pathology Dep., Hacettepe University Faculty of Medicine, 06100 - Ankara/TR
  • 3 Preventive Oncology, Hacettepe University Faculty of Medicine, 06100 - Ankara/TR


Abstract 4238


Diffuse large B-cell lymphoma (DLBCL) accounts for the majority of cases of non-Hodgkin's lymphoma in our country. However, little is known about its clinical and demographic data and prognosis. The aim of this study is to summarize the demographics and to investigate the prognosis of DLBCL patients from a tertiary reference hospital in Turkey over the past 16 years.


This study was designed as a retrospective cohort study. Patient who were diagnosed and/or treated at the University of Hacettepe between 1/2000 and 11/2015 were included. A chart review was conducted to access the clinical and demographic data. Main outcome measures [overall survival (OS), survival after progression (time from relapse to second progression or death, SAP)] were calculated.


A total of 939 cases were included. Mean age of patients was 54 ± 17; 54% of the patients were male and 43.8% were female. Ann Arbor stages at presentation were as follows: stage-1 in 15.8% of patients, stage-2 in 23.4%, stage-3 in 21.1% and 39.7% as stage-4. It is of note that extranodal involvement was prominent (64.6%). The most prevelant extranodal sites were gastrointestinal system (17.3%), central nervous system (4.4%), bone (4.4%), skin (2.4%) and liver (2%). Mean overall survival was 94 ± 12.3 months. At 5 years, 93.2% of patients were alive and at 10 years 85.2% of patients were alive. There was a statistically significant survival difference between stage III and IV patients (p 


Extranodal presentation is more common in DLBCLs in Turkey and clinical parameters such as stage, EN status and BM involvement are the main prognostic factors.

Clinical trial identification

Legal entity responsible for the study





All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings